This session was presented by Foley Partners Catherine Sun and Sharon Barner as well as Chen Meizhang, professor of Peking University, deputy council director of CNIPS (China Intellectual Property Society), director of Peking University IP Institute, and director of Peking University IPR Research Center.
Topics included:
- Different methods a non-Chinese technology-based company can employ to expand to China
- Chinese legal framework for each of the entry options
- Pros and cons of each option
- Role of Chinese regulatory bodies
Related Insights
June 3, 2025
Foley Corporate Governance Update
Texas Senate Bill 2337: Protecting Texas Companies and Their Directors, Shareholders and Boards from Proxy Advice Not in the Financial Interests of Shareholders
On June 2, 2025, the Texas Legislature passed Senate Bill 2337, meaningfully regulating proxy advisors like ISS and Glass Lewis when providing proxy voting recommendations concerning Texas companies.
September 25, 2025
Events
Unclaimed Property Roundtable with Delaware State Escheator and Leading Practitioners
June 3, 2025
Health Care Law Today
GLP-1 Receptor Agonists: The Surge of M&A Activity and the Future of Metabolic Health
Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for metabolic disorders, particularly type 2 diabetes and obesity.